Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
IREN Limited remains a 'Hold' as execution risks and uncertain profitability offset AI tailwinds and Microsoft partnership.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results